Highlighted Publications

Han G*, Deng Q*, Dai E, Dang M, Ma J, Yang H, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie K, Bagaev A, Parmar S, Hagemeister F, Ahmed S, Iyer S, Samaniego F, Steiner R, Fayad L, Lee H, Fowler N, Vega F, Flowers C, Strati P, Westin J, Neelapu S, Nastoupil L, Wang L^§,  Green M^§.  Follicular Lymphoma Microenvironment Characteristics Associated with Tumor Cell Mutations and MHC Class II Expression. Blood Cancer Discovery, 2022;3(5):428-443. PMID: 35687817 (Commentary in Blood Cancer Discovery)

Cherng H, Sun R, Sugg B, Irwin R, Le C, Yang H, Deng Q, Fayad L, Fowler N, Parmar S, Steiner R, Hagemeister F, Nair R, Lee H, Rodriguez M, Samaniego F, Iyer S, Flowers C, Wang L, Nastoupil L, Neelapu S, Ahmed S, Strati P, Green M^§, Westin J^§. Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma. Blood 2022; 140(5):504-515. PMID: 35512184 (Commentary in Blood)

Deng Q*, Han G*, Puebla-Osorio N, Ma M, Strati P, Chasen B, Jain N, Yang H, Wang Y, Zhang S, Wang R, Chen R, Showell J, Ghosh S, Patchva S, Zhang Q, Dai E, Hagemeister F, Fayad L, Saminiego F, Lee H, Nastoupil L, Fowler N, Davis R, Westin J, Neelapu S^§, Wang L^§, Green M^§. Characteristics of anti-CD19 CAR T-cell infusion products associated with efficacy and toxicity in patients with large B-cell lymphomas Nat. Med. 2020;26:878-1887. PMID: 33020644. (Commentary in Nature Medicine, Featured in Cancer Discovery)

Mondello P*, Tadros S*, Teater M, Fontan L, Chang A, Jain N, Singh S, Ma M, Yang H, Toska E, Alig S, Durant M, de Stanchina E, Mottok A, Nastoupil L, Neelapu S, Weigert O, Inghirami G, Baselga J, Dogan A, Younes A, Yee C, Scheinberg D, Melnick A^§, Green M^§. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma. Cancer Discovery, 2020;10(3):440-459. PMID: 31915197.

Jain N^§, Hartert K^§, Tadros S^§, Fiskus W, Havranek O, Ma M, Bouska A, Heavican T, Kumar D, Deng Q, Moore D, Pak C, Liu C, Gentles A, Hartmann E, Kridel R, Smedby K, Juliusson G, Rosenquist R, Gascoyne R, Rosenwald A, Giancotti F, Neelapu S, Westin J, Vose J, Lunning M, Greiner T, Rodig S, Iqbal J, Alizadeh A, Davis R, Bhalla K, Green M. Targetable genetic alterations of TCF4 (E2-2) drive immunoglobulin expression in diffuse large B-cell lymphoma. Sci. Transl. Med. 2019; 11(497): eeav5599. PMID: 31217338. PMCID: PMC6724184.

For a complete list of publications, please see Google Scholar or NCBI.